hapabapa/iStock Editorial via Getty Images
Danish pharma giant Novo Nordisk (NVO) will make a significant investment of approximately $1.2 billion to construct a new production facility in Odense, Denmark.
The new facility will focus on the manufacturing of medications used for rare diseases, including treatments for conditions like haemophilia. The facility will be
